Countless amounts of genetics show advances in precision medicine with the recent expansion of the oncology portfolio and new data presentations at ASCO 2022 - Benzinga

Countless amounts of genetics show advances in precision medicine with the recent expansion of the oncology portfolio and new data presentations at ASCO 2022 – Benzinga


SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) – Myriad Genetics, Inc., MYGNA leader in genetic testing and precision medicine, will present at the annual meeting of the American Society of Clinical Oncology (ASCO) in 2022 a series of studies that will highlight the value of genetic knowledge for leading and clarifying cancer treatment and risk assessment.

The presentations underscore Myriad’s commitment to working with oncologists and other healthcare partners to promote health equity and provide data-based knowledge to help manage clinical care and improve outcomes. They build on the recent launch of Precise-Oncology Solutions, a comprehensive suite of solutions offering germline testing, tumor profiling and accompanying diagnostic options, including homologous recombination deficiency (HRD) assessment. The kit offers simplified testing designed to help oncologists recommend individual treatment plans for their patients.

Precise Oncology Solutions currently includes Myriad’s Precise ™ Tumor Test, MyRisk ™ Hereditary Cancer Test and its two FDA-approved accompanying diagnostic tests: MyChoice® CDx and BRACAanalysis CDx®. The new Precise Treatment Registry combines germline, somatic and HRD genetic data to accelerate the pace of precision cancer research and equitable patient care advancement. In addition, Myriad recently announced that it will expand its strategic partnership with Intermountain Precision Genomics, Intermountain Healthcare, to offer a selective liquid biopsy therapy test in 2023 as part of its growing cancer portfolio.

Myriad Also Highlights ASR MyRisk Leading Cancer Test with Risk Score at ASCO®, the first risk assessment of polygenic breast cancer clinically and analytically validated for women of all ancestors. Providers can gain critical insights to help identify women at increased risk for breast cancer who do not have a harmful mutation in well-known breast cancer genes, such as BRCA1.

“Cancer prevention and treatment are most effective when they are informed about genetic knowledge,” said Thomas Slavin, MD, chief physician, Myriad Genetics. “Our recent portfolio expansion and presentation at ASCO underscore our efforts to continually grow and innovate to better support physicians with comprehensive data-driven responses that inform treatment, reduce healthcare disparities, and improve outcomes for all patients.”

Data from Myriad that will be presented at the meeting:

Breast cancer (BC) risk model including Tyrer-Cuzick version 8 (TCv8) and polygenic risk scores for various ancestors (Abstract # 366104)
Session type: Poster session
Date: Monday, June 6, 2022
Time: 8: 00-11: 00 CDT

This is the first breast cancer risk model to include breast density, family history, and polygenic risk score (PRS) based on genetically determined origin, which is validated for different populations. The addition of PRS has significantly improved risk stratification over TCv8 alone and may allow for a more personalized approach to reducing breast cancer risk.

Gender-specific risk of triple-negative breast cancer (TNBC) associated with germline pathogenic variants (PV) in hereditary carcinoma (CA) predisposition genes (Abstract # 377784)
Session type: Poster discussion
Date: Monday, June 6, 2022
Time: 16: 30-18: 00; 13: 15-16: 15 CDT

In this population of women who had multigene panel testing, there were pathogenic variants in BRCA1, BRCA2, PALB2, RAD51C, RAD51Dand BARD1 were associated with a significant risk of triple-negative breast cancer (TNBC). No significant differences in ancestral pathogenic TNBC risks were found. TNBC has been reported more frequently in women of African descent.

Investigation of homologous recombination deficit thresholds for prediction of platinum-based treatment response in triple-negative breast cancer (Abstract # 364894)
Session type: Poster session
Date: Monday, June 6, 2022
Time: 8: 00-11: 00 CDT

This exploratory analysis evaluated the ability of ≥ 33 or ≥ 42 genomic instability (GIS) thresholds to predict platinum-based treatment response in patients with triple-negative breast cancer. This study 204 mixed tumors BRCA wild type BRCA mutations and unknowns have shown that GIS ≥ 33 may be the most appropriate threshold for predicting response to platinum-based therapy in TNBC patients; however, a prospective study is needed.

Adherence to EndoPredict Extended Endocrine Therapy Test Results in a Prospective EndoPredict Extended Endocrine Study (EXET) (Abstract # 371368)
Session type: Poster session
Date: Monday, June 6, 2022
Time: 8:00 – 11:00 CDT

In this cohort of patients, although other clinical factors such as nodal status, tumor grade, age at diagnosis, and other variables were taken into account, the EndoPredict® Breast Cancer Prognostic Test provided Myriad with important information for clinical decisions on advanced endocrine therapy.

About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to improving health and well-being for all. Myriad develops and commercializes genetic tests that help assess risk of disease progression or progression, and guide treatment decisions across medical specializations, where genetic knowledge can significantly improve patient care and reduce healthcare costs. A fast company called Myriad between The world’s most innovative companies for 2022. For more information, visit www.myriad.com.

Myriad, logo Myriad, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Riskriscore, Prolluminated. , GeneSight and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. © 2022 Myriad Genetics, Inc. All rights reserved.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act 1995, including statements regarding the company submitting several studies at the ASCO Annual Meeting in 2022, an extension of the company’s strategic partnership with Intermountain Precision Genomics . to offer a selective liquid biopsy therapy test in 2023, the company’s plan to highlight a validation study for its MyRisk Hereditary Cancer Test with RiskScore at the ASCO Annual Meeting in 2022, and the company’s strategic imperatives under the title “About Myriad Genetics.” These “forward-looking statements” are management’s current expectations about future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in these forward-looking statements. These risks include, but are not limited to: the uncertainties associated with COVID-19, including its potential impact on the Company’s operations and demand for its products and services, and on the Company’s ability to manage its business efficiently and flexibly; the risk that sales and profit margins of the Company’s existing molecular diagnostic tests may decline or that the Company may not be able to conduct its business on a profitable basis; risks related to the company’s ability to generate sufficient revenue from its existing product portfolio or when introducing and commercializing new tests; the risks associated with changes in the coverage of government or private insurers and the level of reimbursement for the Company’s tests or the Company’s ability to obtain reimbursement for its new tests at a level comparable to its existing tests; risks associated with increased competition and the development of new competitive tests and services; the risk that the company may not be able to develop or achieve commercial success for further molecular diagnostic tests in a timely manner or at all; the risk that the Company may not successfully develop new markets for its molecular diagnostic tests, including the Company’s ability to successfully generate revenue outside the United States; the risk that the license for the technology on which the Company’s molecular diagnostic tests are based and any future tests will be terminated or will not be maintained under satisfactory conditions; risks related to delays or other problems with the operation and construction of the company’s laboratory test facilities; risks related to public concerns about genetic testing in general or society tests in particular; risks related to regulatory requirements or enforcement in the United States and abroad and changes in the structure of the health care system or health care payment systems; the risks associated with the company’s ability to acquire new business cooperation or licenses and to acquire or develop new technologies or businesses on satisfactory terms, if at all; risks related to the Company’s ability to successfully integrate and benefit from any technology or enterprise that it licenses, acquires or develops; risks associated with the company’s projections of potential market opportunities for the company’s current and future products; the risk that the Company or its licensors may not be able to protect or that third parties infringe the patented technologies on which the Company’s tests are based; the risk of patent infringement claims or challenge to the validity of the company’s patents; the risks associated with changes in intellectual property laws relating to the company’s molecular diagnostic tests or patents or law enforcement in the United States and abroad; risks related to security breaches, data loss and other breaches, including cyber attacks; the risks of new, changing and competing technologies and regulations in the United States and internationally; the risk that the company may not be able to meet its financial operating obligations under the company’s credit or borrowing agreements; the risks associated with significant deficiencies related to general IT controls, including their impact and the company’s remediation plan, and its ability to achieve and maintain effective controls and procedures for the disclosure and internal control of financial reporting; risks related to current and future litigation, including product or professional liability claims; and other factors discussed under the heading “Risk Factors” in Section 1A of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on February 25, 2022, as well as any updates to these risk factors from time to time in quarterly company reports on Form 10-Q or in current reports on Form 8-K.


Primary logo



Source link

Leave a Comment

Your email address will not be published.